These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26687858)

  • 21. Chronic traumatic encephalopathy: The unknown disease.
    Martínez-Pérez R; Paredes I; Munarriz PM; Paredes B; Alén JF
    Neurologia; 2017 Apr; 32(3):185-191. PubMed ID: 25534950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET/CT in diagnosis of dementia.
    Berti V; Pupi A; Mosconi L
    Ann N Y Acad Sci; 2011 Jun; 1228():81-92. PubMed ID: 21718326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias.
    Taswell C; Villemagne VL; Yates P; Shimada H; Leyton CE; Ballard KJ; Piguet O; Burrell JR; Hodges JR; Rowe CC
    J Nucl Med; 2015 Oct; 56(10):1547-53. PubMed ID: 26251415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET/MR in dementia and other neurodegenerative diseases.
    Barthel H; Schroeter ML; Hoffmann KT; Sabri O
    Semin Nucl Med; 2015 May; 45(3):224-33. PubMed ID: 25841277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The utility of PET brain imaging in the initial evaluation of dementia.
    Weaver JD; Espinoza R; Weintraub NT
    J Am Med Dir Assoc; 2007 Mar; 8(3):150-7. PubMed ID: 17349943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Will PET amyloid imaging lead to overdiagnosis of Alzheimer dementia?
    Dubroff JG; Nasrallah IM
    Acad Radiol; 2015 Aug; 22(8):988-94. PubMed ID: 26100192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of positron emission tomography/computed tomography in dementia.
    Hinds SR; Stocker DJ; Bradley YC
    Radiol Clin North Am; 2013 Sep; 51(5):927-34. PubMed ID: 24010914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Voyage au bout de la nuit: Aβ and tau imaging in dementias.
    Zwan MD; Okamura N; Fodero-Tavoletti MT; Furumoto S; Masters CL; Rowe CC; Villemagne VL
    Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):398-412. PubMed ID: 25358680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyloid imaging for dementia in clinical practice.
    O'Brien JT; Herholz K
    BMC Med; 2015 Jul; 13():163. PubMed ID: 26170121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management impact of FDG-PET in dementia: results from a tertiary center memory clinic.
    Elias A; Woodward M; Rowe CC
    J Alzheimers Dis; 2014; 42(3):885-92. PubMed ID: 24961944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index.
    Döbert N; Pantel J; Frölich L; Hamscho N; Menzel C; Grünwald F
    Dement Geriatr Cogn Disord; 2005; 20(2-3):63-70. PubMed ID: 15908747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear medicine imaging in dementia: a practical overview for hospitalists.
    Toney LK; McCue TJ; Minoshima S; Lewis DH
    Hosp Pract (1995); 2011 Aug; 39(3):149-60. PubMed ID: 21881402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The neuropathology and neurobiology of traumatic brain injury.
    Blennow K; Hardy J; Zetterberg H
    Neuron; 2012 Dec; 76(5):886-99. PubMed ID: 23217738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of molecular imaging on the diagnostic process in a memory clinic.
    Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
    Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accumulation of amyloid in cognitive impairment after mild traumatic brain injury.
    Yang ST; Hsiao IT; Hsieh CJ; Chiang YH; Yen TC; Chiu WT; Lin KJ; Hu CJ
    J Neurol Sci; 2015 Feb; 349(1-2):99-104. PubMed ID: 25586534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear medicine diagnostic techniques in the era of pathophysiology-based CSF biomarkers for Alzheimer's disease.
    Weih M; Degirmenci U; Kreil S; Suttner G; Schmidt D; Kornhuber J; Lewczuk P; Kuwert T
    J Alzheimers Dis; 2011; 26 Suppl 3():97-103. PubMed ID: 21971454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography in at risk patients and in the progression of mild cognitive impairment to Alzheimer's disease.
    Rinne JO; Någren K
    J Alzheimers Dis; 2010; 19(1):291-300. PubMed ID: 20061645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alzheimer disease and cerebrovascular pathology: an update.
    Jellinger KA
    J Neural Transm (Vienna); 2002 May; 109(5-6):813-36. PubMed ID: 12111471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of functional imaging in Parkinsonism and dementia.
    Burn DJ; O'Brien JT
    Mov Disord; 2003 Sep; 18 Suppl 6():S88-95. PubMed ID: 14502661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.